Background: The 8th edition of the AJCC TNM staging system for gastric cancer was released in 2016 and included major revisions, especially of stage III.
Patients And Methods: Data from 3281 patients with GC who underwent R0 resection between December 2006 and November 2014 were reviewed. Of them, 1579 patients with stage III according to the seventh edition were analyzed and the 7th and 8th TNM classifications were compared.
Results: The most important tumor stages change observed in stage III GC. For stage III patients, the median number of lymph nodes (LNs) resected in stage III patients was 33 (range 5-112), and the optimal cut-off value for the number of LNs resected was 30. Although the 7th edition classification had higher c-index, linear trend and likelihood ratio χ scores, and smaller AIC values compared with those for the 8th edition, which represented the optimum prognostic stratification, however, the differences between 7th and 8th edition seems to be not statistically significant, and AIC demonstrates similar trend as well. Further subgroup analysis found that the 8th staging system generated the marginally better prognostic stratification only when LNs removed ≥30.
Conclusion: The 8th TNM classification may provide better accuracy than 7th edition in predicting the prognosis of stage III GC after R0 resection with LNs harvested ≥30. However, further research in an external validation setting is warranted.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ejso.2017.09.001 | DOI Listing |
J Gastrointest Cancer
January 2025
Colorectal Research Center, Imam Khomeini Hospital complex, Tehran University of Medical Sciences, Keshavarz Blvd, Tehran, Iran.
Purpose: Carcinoembryonic antigen (CEA) is an important prognostic factor for rectal cancer. This study aims to introduce a novel cutoff point for CEA within the normal range to improve prognosis prediction and enhance patient stratification in rectal cancer patients.
Methods: A total of 316 patients with stages I to III rectal cancer who underwent surgical tumor resection were enrolled.
Immunotherapy
January 2025
Department of Surgery, Division of Surgical Oncology, Roger Williams Medical Center, Providence, RI, USA.
Introduction: Significant gains in advanced melanoma have been made through immunotherapy trials. Factors influencing equitable access and survival impact of these novel therapies are not well-defined.
Method: Retrospective analysis using National Cancer Database of patients with advanced stage III and IV melanoma from 2004 to 2021.
Sci Rep
January 2025
Department of Oncology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, No. 17 Yongwaizheng Street, Nanchang, 330006, Jiangxi Province, China.
The benefit of adjuvant chemotherapy (CT) for hormone receptor-negative T1a and T1bN0M0 breast cancer remains uncertain. Our study was to explore prognostic value and identify candidates of adjuvant CT for these patients. The data of hormone receptor-negative T1a and T1bN0M0 breast cancer patients were extracted from the Surveillance, Epidemiology, and End Results (SEER) database from 2010 to 2015.
View Article and Find Full Text PDFClin Lung Cancer
December 2024
Indiana University Simon Cancer Center, Indianapolis, IN. Electronic address:
Background: Immunotherapy has been widely incorporated into the treatment of patients with non-small-cell lung cancer (NSCLC). Many of these patients will experience immune-related adverse events (irAEs) without decreased efficacy. We report a retrospective analysis of the association between irAEs and efficacy outcomes from the BTCRC LUN 16-081 randomized phase 2 trial of consolidation nivolumab (N) plus ipilimumab (IPI) vs N alone following chemoradiotherapy in unresectable Stage IIIA/IIIB NSCLC.
View Article and Find Full Text PDFEur J Obstet Gynecol Reprod Biol
January 2025
Medical Oncology Department, Marqués de Valdecilla University Hospital, IDIVAL, Cantabria, Spain.
Objectives: To assess the recurrence rate and quality of life (QOL) in women with a history of borderline ovarian tumours (BOTs) based on the type of surgery (conservative vs non-conservative) in Spain.
Study Design: A retrospective analysis was conducted of 85 women treated for BOTs between 2007 and 2023 at two hospitals. QOL questionnaires were administered face-to-face to eligible patients.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!